Kidney Transplant News and Research

RSS

A kidney transplant is an operation where a healthy kidney from one person (the donor) is transferred to a person who has little or no kidney function (the recipient).

Researchers unveil prototype model of first implantable artificial kidney

UCSF researchers today unveiled a prototype model of the first implantable artificial kidney, in a development that one day could eliminate the need for dialysis.

3 Sep 2010

Blood pressure treatment may prevent end-stage kidney disease in some patients: Study

Intensively treating hypertension in some African Americans with kidney disease by pushing blood pressure well below the current recommended goal may significantly decrease the number who lose kidney function and require dialysis, suggests a Johns Hopkins-led study publishing in the New England Journal of Medicine Thursday.

2 Sep 2010

Beaumont Hospital expands new multi-organ transplant program

Beaumont Hospital, Royal Oak became Michigan's third liver transplant center on Aug. 31. A 59-year-old man from Royal Oak was the first patient to receive a liver transplant through Beaumont's new multi-organ transplant program.

2 Sep 2010

Non-kidney transplant patients likely to undergo kidney transplant prior to dialysis: Study

Kidney failure may accompany or complicate transplantation of the liver, heart, or lung. Because increasing numbers of individuals are receiving non-kidney transplants, researchers have wondered whether more of such patients are being listed for kidney transplants.

2 Sep 2010

BioTrends Research Group report provides in-depth view of kidney transplantation market

BioTrends Research Group, Inc. recently published its TreatmentTrends: Kidney Transplantation report. This report is based on online survey results from over 150 physicians (general nephrologists, transplant nephrologists and transplant surgeons). It provides an in-depth view of the kidney transplantation market, including the roles of the various specialties, promotional efforts and sales representative messaging, barriers to kidney transplant, the care of post-transplant patients, and current and projected use of immunosuppressive agents for induction, maintenance and acute rejection.

26 Aug 2010

3Sbio, Isotechnika Pharma sign development and commercialization agreement for voclosporin inhibitor

Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, and 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the signing of a development and commercialization agreement for voclosporin, a next generation calcineurin inhibitor being developed for use in the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.

25 Aug 2010

3SBio and Isotechnika enter strategic agreement for voclosporin in China

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products and Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, today announced the signing of a development and commercialization agreement for voclosporin.

24 Aug 2010

Removing corticosteroid regimen after surgery results in better graft survival rates

University of Cincinnati (UC) analysis of 10 years of data from local kidney transplant patients shows that patients removed from a corticosteroid regimen shortly after surgery have better graft survival rates, better survival rates and fewer cardiovascular events than patients kept on the traditional regimen of long-term steroids.

24 Aug 2010

NBA player Alonzo Mourning uses celebrity fame to fight kidney disease

In October 2000, Mourning was diagnosed with focal segmental glomerular sclerosis (FSGS), a kidney disease that causes scarring in the glomeruli, the blood vessels in the kidneys that filter the blood to make urine.

21 Aug 2010

Racial disparities exist among living kidney donors, post donation: Research

Black and Hispanic kidney donors are significantly more likely than white donors to develop hypertension, diabetes and chronic kidney disease, according to new Saint Louis University research published in the August 19, 2010 issue of the New England Journal of Medicine.

20 Aug 2010

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

Silence Therapeutics plc, a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc., has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.

20 Aug 2010

Donor kidneys from deceased as good as those from brain-dead: Study

According to a new study from the UK, transplanted kidneys from patients whose hearts have stopped perform just as well as those from patients who are brain-dead but still alive. The former have been earlier considered to be weaker since the heart had stopped pumping blood into them before transplant. The study was published online by the The Lancet.

20 Aug 2010

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.

18 Aug 2010

FDA grants orphan drug designation to NephRx's lead product NX001

NephRx Corporation today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product NX001 for the prevention of delayed graft function in renal transplant recipients. NX001 is a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure.

18 Aug 2010

BrickHouse Security, National Kidney Registry implement real-time GPS tracking system for organ shipment

BrickHouse Security, a leading provider of security and surveillance products to businesses and consumers, today announced that, in partnership with the National Kidney Registry (NKR), they have implemented the first real-time GPS tracking system for the shipment of living donor organs.

17 Aug 2010

Belatacept study data to be presented at 23rd International Congress of The Transplantation Society

Bristol-Myers Squibb Company announced today that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of seven oral clinical presentations related to kidney transplantation at the 23rd International Congress of The Transplantation Society, being held August 15-19, 2010, in Vancouver, British Columbia, Canada. In total, 18 abstracts from company-sponsored studies will be presented during the congress.

16 Aug 2010

FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients

LifeCycle Pharma A/S today announced receipt of agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment of its pivotal Phase 3 study, Study 3002, for LCP-Tacro in patients, who have just received a kidney transplant.

12 Aug 2010

Tengion announces clinical, corporate and second-quarter financial updates

Tengion Inc. today provided a corporate and product development update and reported its financial results for the quarter ended June 30, 2010.

12 Aug 2010

Stanford Hospital & Clinics establishes Kidney and Pancreas Transplant Clinic at Salinas Valley Memorial

The partnership between Salinas Valley Memorial Healthcare System and Stanford Hospital & Clinics has added another facet of care, bringing world-class organ transplant care to patients on the Central Coast. Stanford's Adult Kidney and Pancreas Transplant Program will begin seeing patients at Salinas Valley Memorial's Ryan Ranch facility.

11 Aug 2010

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) approved increasing the length of therapy with Valcyte (valganciclovir hydrochloride) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

11 Aug 2010

Kidney Transplant News and Research

Further Reading

Researchers unveil prototype model of first implantable artificial kidney

Blood pressure treatment may prevent end-stage kidney disease in some patients: Study

Beaumont Hospital expands new multi-organ transplant program

Non-kidney transplant patients likely to undergo kidney transplant prior to dialysis: Study

BioTrends Research Group report provides in-depth view of kidney transplantation market

3Sbio, Isotechnika Pharma sign development and commercialization agreement for voclosporin inhibitor

3SBio and Isotechnika enter strategic agreement for voclosporin in China

Removing corticosteroid regimen after surgery results in better graft survival rates

NBA player Alonzo Mourning uses celebrity fame to fight kidney disease

Racial disparities exist among living kidney donors, post donation: Research

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

Donor kidneys from deceased as good as those from brain-dead: Study

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

FDA grants orphan drug designation to NephRx's lead product NX001

BrickHouse Security, National Kidney Registry implement real-time GPS tracking system for organ shipment

Belatacept study data to be presented at 23rd International Congress of The Transplantation Society

FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients

Tengion announces clinical, corporate and second-quarter financial updates

Stanford Hospital & Clinics establishes Kidney and Pancreas Transplant Clinic at Salinas Valley Memorial

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News